Molecule News and Research

RSS

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies.

7 Nov 2013

MGH researchers identify probable mechanism for pain-induced cognitive impairment

The pain caused by a surgical incision may contribute to the risk of postoperative cognitive dysfunction, a sometimes transient impairment in learning and memory that affects a small but significant number of patients in the days following a surgical procedure.

7 Nov 2013

Researchers on the way to find cure against African sleeping sickness

Researchers at Umeå University have identified drugs targeting infections of the parasite Trypanosoma brucei and are thereby well on the way to find a cure against African sleeping sickness. This is the kernel of a thesis, which will be publicly defended on 8 November 2013.

6 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Offspring born to stressed mothers show stress-induced changes

Children of survivors of extremely stressful life events face adjustment challenges of their own, as has been most carefully studied among the children of Nazi Death Camp survivors. This "intergenerational" transmission of stress response has been studied predominately from the psychological perspective. However, recent research points to biological contributions as well.

5 Nov 2013

Researchers identify factor that promotes metastasis of colon tumors

Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified a factor that promotes metastasis of colon tumors - and presents a possible target for therapy.

5 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

LMU researchers identify a factor that promotes metastasis of colon tumors

Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet in Munich have identified a factor that promotes metastasis of colon tumors - and presents a possible target for therapy.

4 Nov 2013

Probiotics may help keep bad germs at bay

Microbes are everywhere - thousands of species are in your mouth, and thousands are in a glass of tap water. The ones in your mouth are mostly harmless - as long as you brush and floss so they don't form a biofilm that allows gum disease a path into the blood stream.

4 Nov 2013

New therapeutic approach for treating type 2 diabetes

Scientists from the Helmholtz Zentrum München (HMGU) and the Technische Universität München (TUM), together with scientists in the USA, have developed a new therapeutic approach for treatment of type 2 diabetes.

31 Oct 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013

Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be presenting new data at Neuroscience 2013, 9-13 November, San Diego (USA).

From Cellectricon 31 Oct 2013

New finding could help lead to better treatments for eczema

For the millions of people suffering from the intensely red, horribly itchy skin condition known as eczema, the only thing more maddening than their disease is the lack of understanding of what causes it, or makes it flare up from time to time.

31 Oct 2013

Scientists develop new therapeutic approach for treatment of type 2 diabetes

Scientists from the Helmholtz Zentrum Muenchen and the Technische Universitaet Muenchen, together with scientists in the USA, have developed a new therapeutic approach for treatment of Type 2 diabetes. A novel single molecule hormone, which acts equally on the receptors of the insulin-stimulating hormones GLP-1 and GIP, was observed to reduce weight and improve blood sugar.

31 Oct 2013

Research findings open up possibility for developing potent anti-clotting drugs

Researchers at the University of Illinois at Chicago have discovered a molecular switch that causes small, beneficial clots that stop bleeding to enlarge further during wound healing. By blocking this switch in lab mice, the researchers prevented small clots from growing -- a process that can pose a danger in humans -- while preserving their ability to staunch bleeding

29 Oct 2013

Pulmatrix reports positive results from initial PUR0200 Phase IB clinical study in COPD

Pulmatrix today announced the successful completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200.

29 Oct 2013

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Inc. today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012. Non-GAAP diluted EPS for the third quarter of 2013 were $2.35, an increase of 23% over the third quarter of 2012.

28 Oct 2013

Apremilast drug shows promise for Behcet's ulcers

Apremilast, an orally available small molecule modulating several inflammatory pathways, which is pending approval by the United States Food and Drug Administration, is showing promise in the treatment of mouth and genital ulcers in people with Behcet's syndrome, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego.

28 Oct 2013

Scientists develop new drug to treat obstructive airway diseases

Scientists have developed a new drug (RPL554) that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease in two ways at once, according to new research published in The Lancet Respiratory Medicine.

25 Oct 2013

Common food additive can block new strain of avian influenza virus

A common food additive can block a deadly new strain of avian influenza virus from infecting healthy cells, report researchers at the University of Illinois at Chicago College of Medicine in the online journal, PLOS ONE.

24 Oct 2013